Early Approval For Astra's Asthma Drug Stuns Analysts

Law360, New York (July 22, 2006, 12:00 AM EDT) -- In a blow to GlaxoSmithKline Plc, rival AstraZeneca Plc has secured a surprisingly early U.S. Food and Drug Administration approval for Symbicort, an asthma drug that will compete directly with Glaxo’s blockbuster asthma treatment Advair.

AstraZeneca applied for FDA approval last September and had expected a turnaround time of about one to two years, which would be typical for a new asthma inhaler.

The FDA approved two dose strengths of the treatment for asthma in patients age 12 and older, but AstraZeneca won’t launch the drug...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.